| abstract |
1,5 Benzodiazepine compounds of formula (I), where R1 is selected from C¿1?-C6alkyl, C3-C6cycloalkyl, phenyl, or substituted phenyl; R?2¿ is selected from C¿3?-C6alkyl, C3-C6cycloalkyl, C3-C6alkenyl, benzyl, phenylC1-C3alkyl or substituted phenyl; or NR?1R2¿ together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C¿1-6?alkyl, C1-6alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R?3, R5 and R6¿ are independently hydrogen or C¿1-6?alkyl; R?4¿ is C¿1-6?alkyl or C1-6alkenyl; R?7¿ is selected from the group consisting of hydrogen, C¿1-6?alkyl, C1-6cycloalkyl, C1-6alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR?6R7¿ together form a saturated 5, 6 or 7 membered ring optionally interrupted by 1, 2, 3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other; m is an integer selected from the group of 0, 1, 2, 3 or 4; R?8 and R9¿ are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I). |